21st Aug 2014 08:36
LONDON (Alliance News) - Hutchison China MediTech Ltd Thursday said Hutchison MediPharma Ltd, its majority owned drug research and development company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in colorectal cancer in China.
The company said the proof-of-concept study is investigating the efficacy and safety of fruquintinib, Hutchison MediPharma's investigational small molecule inhibitor of vascular endothelial growth factor receptors.
This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with metastatic colorectal cancer, who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan.
A total of 71 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus best supportive care at a 2:1 ratio.
Hutchison said the primary endpoint is progression-free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety.
Data from this trial are expected early next year.
Hutchison China MediTech shares were quoted up 1.0% at 1,020.00 pence Thursday morning.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed